Trial reportScandinavian journal of urology2018
Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
Trial report in Scandinavian journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.The Journal of urology · 2023Guideline
- Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review.Frontiers in oncology · 2023Pooled it
- Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.The Journal of urology · 2022Trial
- Trial
- A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.European urology · 2019Trial
- Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Prostate Cancer Mortality in Men not Attending a Population-based Screening Program: The 'Good', the 'Bad', and the 'Ugly' After 20-yr Follow-up in the European Randomised study of Screening for Prostate Cancer.European urology open science · 2026Article
- Uncovering genes driving developmental stage progression in prostate cancer through spatial transcriptomics.Genes & diseases · 2026Article
- [Reducing overdiagnosis-how to do I correctly assess the indication for prostate biopsy?]Urologie (Heidelberg, Germany) · 2026Review
- External Validation of the PROMOD Strategy, Combining PI-RADS Score and PSA Density, to Select Patients for Prostatic Biopsies.Research and reports in urology · 2026Article
- Multilevel associations between prostate cancer testing and socioeconomic position: a population-based register study from Stockholm, Sweden.BMJ public health · 2026Article
- Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- From bench to bedside: the evolution and future of prostate-specific antigen testing.Medical oncology (Northwood, London, England) · 2025Review
- Is it time for Canada to revisit its approach to prostate cancer screening?Lancet regional health. Americas · 2025Review
- Association of height, BMI, and smoking status with prostate cancer risk before and after the introduction of PSA testing in Sweden.Scientific reports · 2025Article
- Prostate cancer screening in transgender patients Why current Canadian screening policies need to be better tailored to our patients.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Sociodemographic disparities in incidence rates of advanced and low-risk prostate cancer as a proxy for diagnostic activity.Acta oncologica (Stockholm, Sweden) · 2025Article
- Prostate cancer screening in the Middle East and North Africa: a cross-sectional study on current practices.JNCI cancer spectrum · 2025Article
- [Early detection of prostate cancer-individualized, risk-adapted and successful].Urologie (Heidelberg, Germany) · 2025Review
- Prostate cancer diagnostics: evolution over 30 years and the impact of education level - a prospective population-based study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study examined whether previously reported results, indicating that prostate-specific antigen (PSA) screening can reduce prostate cancer (PC) mortality regardless of sociodemographic inequality, could be corroborated in an 18 year follow-up. MATERIALS AND
methodsIn 1994, 20,000 men aged 50-64 years were randomized from the Göteborg population register to PSA screening or control (1:1) (study ID: ISRCTN54449243). Men in the screening group (n = 9950) were invited for biennial PSA testing up to the median age of 69 years. Prostate biopsy was recommended for men with PSA ≥2.5 ng/ml. Last follow-up was on 31 December 2012.
resultsIn the screening group, 77% (7647/9950) attended at least once. After 18 years, 1396 men in the screening group and 962 controls had been diagnosed with PC [hazard ratio 1.51, 95% confidence interval (CI) 1.39-1.64]. Cumulative PC mortality was 0.98% (95% CI 0.78-1.22%) in the screening group versus 1.50% (95% CI 1.26-1.79%) in controls, an absolute reduction of 0.52% (95% CI 0.17-0.87%). The rate ratio (RR) for PC death was 0.65 (95% CI 0.49-0.87). To prevent one death from PC, the number needed to invite was 231 and the number needed to diagnose was 10. Systematic PSA screening demonstrated greater benefit in PC mortality for men who started screening at age 55-59 years (RR 0.47, 95% CI 0.29-0.78) and men with low education (RR 0.49, 95% CI 0.31-0.78).
conclusionsThese data corroborate previous findings that systematic PSA screening reduces PC mortality and suggest that systematic screening may reduce sociodemographic inequality in PC mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.